Sydney M Crago

Patricio Schlottmann highlights promising long-term results of faricimab for wet AMD, showcasing sustained visual gains and excellent safety in patients.

Miere discusses retinal studies on AMD and vein occlusion, highlighting imaging advancements and the future of machine learning in treatment predictions.

Explore the Fight Retinal Blindness! Project, a global registry enhancing VEGF inhibitor treatment outcomes with comprehensive data and insights for better patient care.

Explore how digital image management and AI transform ophthalmology, enhancing diagnostics and personalizing patient care in retina practices.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

A new staging system for diabetic retinopathy and macular edema is essential, integrating advanced imaging techniques for better disease management and patient outcomes.

The future of diabetic retinal imaging will be impacted by the use of widefield OCT-A technology, enhancing diagnosis and monitoring while addressing current limitations.

Timothy Lai, MD, shares promising one-year results from the SALWEEN study on faricimab for polypoidal choroidal vasculopathy at EURETINA 2025.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a non-invasive method for identifying high-risk patients through retinal analysis.

Identifeye HEALTh is taking on retinal imaging, enhancing accessibility and integrating AI to improve patient care and streamline healthcare workflows.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

MCO-010 receives Orphan and RMAT designations, highlighting its potential as a groundbreaking therapy for various retinal dystrophies.

Jeremiah Tao, MD, FACS, highlights essential safety strategies in oculofacial surgery, emphasizing cost-effective techniques to prevent complications and enhance patient care.